Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels